Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

Summary

The purpose of this study was to measure the long-term safety and efficacy profile of LTP001 in participants with pulmonary arterial hypertension (PAH). The study offered participants who had completed the CLTP001A12201 double-blind parent study in PAH an opportunity to receive LTP001 (whether they were on LTP001 or not). Unblinding of the treatment received in CLTP001A12201 was generally not needed but could occur on request by the investigator.

Timeline

Start

2023-03-27

Primary completion

2024-04-26

Completion

2024-05-14

Drugs

Indications